Gongyan Chen
About
Gongyan Chen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Gongyan Chen has authored 48 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Gongyan Chen's work include Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Research Studies (19 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Gongyan Chen is often cited by papers focused on Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Research Studies (19 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Gongyan Chen collaborates with scholars based in China, United States and Hong Kong. Gongyan Chen's co-authors include Yi‐Long Wu, Jianxing He, Shun Lü, Ying Cheng, Baohui Han, Caicun Zhou, Jifeng Feng, Cheng Huang, Jin‐Ji Yang and Yong Song and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Cell.
In The Last Decade
Gongyan Chen
47 papers receiving 1.4k citations
Peers
Gongyan Chen
Yuichi Sakamori Japan
Shunsuke Teraoka Japan
Elizabeth Dudnik Israel
Keita Kudo Japan
Ryoji Kato Japan
Fausto Barbieri Italy
Epaminontas Samantas Greece
Ryo Toyozawa Japan
Fernando C. Santini United States
Jean-Louis Pujol France
Citations per year, relative to Gongyan Chen Gongyan Chen (= 1×)
peers
Yuichi Sakamori
Countries citing papers authored by Gongyan Chen
Since
Specialization
Citations
This map shows the geographic impact of Gongyan Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gongyan Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gongyan Chen more than expected).
Fields of papers citing papers by Gongyan Chen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gongyan Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gongyan Chen. The network helps show where Gongyan Chen may publish in the future.
Co-authorship network of co-authors of Gongyan Chen
This figure shows the co-authorship network connecting the top 25 collaborators of Gongyan Chen. A scholar is included among the top collaborators of Gongyan Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gongyan Chen. Gongyan Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wu, Lin, Yinghua Ji, Gongyan Chen, et al.. (2025). Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial. The Lancet Respiratory Medicine. 13(8). 677–686.
2.
Wu, Yi‐Long, Shun Lü, Gongyan Chen, et al.. (2024). IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer. Chinese Journal of Cancer Research. 36(2). 103–113.
3.
Cheng, Ying, Qiming Wang, Kai Li, et al.. (2023). Third‐line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double‐blind phase 2 study. SHILAP Revista de lepidopterología. 2(3). 181–190.
4.
Lü, Shun, Chuan Li, Hong Jian, et al.. (2023). Abstract 5462: Elevated creatine phosphokinase (CPK) as a strong predictor of aumolertinib (Au) treatment response in patients (pts) with advanced non-small cell lung cancer (NSCLC): post-hoc analysis of AENEAS. Cancer Research. 83(7_Supplement). 5462–5462.
5.
Shi, Yuankai, et al.. (2023). Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801). SHILAP Revista de lepidopterología. 2(2). 103–111.
6.
Zhang, Li, Zhehai Wang, Jian Fang, et al.. (2022). Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study. Lung Cancer. 171. 56–60.
7.
Gao, Guanghui, Jun Zhao, Shengxiang Ren, et al.. (2022). Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer. Annals of Translational Medicine. 10(8). 441–441.
8.
Liu, Ying, Ying Cheng, Qiming Wang, et al.. (2021). Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study. Thoracic Cancer. 12(22). 3039–3045.
9.
Cheng, Ying, Qiming Wang, Kai Li, et al.. (2021). Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. British Journal of Cancer. 125(3). 366–371.
10.
Zhou, Qing, Chong‐Rui Xu, Ying Cheng, et al.. (2021). Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. 39(9). 1279–1291.e3.
11.
Lü, Shun, Xiaorong Dong, Hong Jian, et al.. (2021). Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).. Journal of Clinical Oncology. 39(15_suppl). 9013–9013.
12.
Tao, Xingyu, Jinbao Liu, Gongyan Chen, et al.. (2021). The Monitoring and Early Warning System of Geological Disaster Mass Survey and Prevention in Linzhi. 376–379.
13.
Liu, Yang, Ying Cheng, Kai Li, et al.. (2021). Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial. Translational Lung Cancer Research. 10(9). 3793–3806.
14.
Yang, Jin‐Ji, Jian Fang, Yongqian Shu, et al.. (2020). A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. Investigational New Drugs. 39(2). 477–487.
15.
Cong, Minghua, Hongxia Xu, Chunhua Song, et al.. (2020). The patient-generated subjective global assessment is a promising screening tool for cancer cachexia. BMJ Supportive & Palliative Care. 12(e1). e39–e46.
16.
Wu, Yi‐Long, Li Zhang, Yun Fan, et al.. (2020). Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study. International Journal of Cancer. 148(9). 2313–2320.
17.
Zhou, Qing, Ming Chen, Gang Wu, et al.. (2020). GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/ unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Translational Lung Cancer Research. 9(5). 2008–2015.
18.
Wang, Meng, Yicun Wang, Song Gao, et al.. (2017). CXCL12 suppresses cisplatin-induced apoptosis through activation of JAK2/STAT3 signaling in human non-small-cell lung cancer cells. OncoTargets and Therapy. Volume 10. 3215–3224.
19.
Wu, Yi‐Long, Jin Yang, Caicun Zhou, et al.. (2017). PL03.05: BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201). Journal of Thoracic Oncology. 12(1). S6–S6.
20.
Zhao, Hong-Yun, Gongyan Chen, Yan Huang, et al.. (2015). Erlotinib Plus Capecitabine as First-Line Treatment for Older Chinese Patients With Advanced Adenocarcinoma of the Lung (C-TONG0807). Medicine. 94(2). e249–e249.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yuichi Sakamori Breakdown of academic impact, for papers by Shunsuke Teraoka Breakdown of academic impact, for papers by Elizabeth Dudnik Breakdown of academic impact, for papers by Keita Kudo Breakdown of academic impact, for papers by Ryoji Kato Breakdown of academic impact, for papers by Fausto Barbieri Breakdown of academic impact, for papers by Epaminontas Samantas Breakdown of academic impact, for papers by Ryo Toyozawa Breakdown of academic impact, for papers by Fernando C. Santini Breakdown of academic impact, for papers by Jean-Louis Pujol